Characterization of mental health in cannabis dispensary users, using structured clinical interviews and standardized assessment instruments.
Cannabis
Clinical interview
Dispensary
MINI
Mental health
Psychiatric symptoms
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
received:
25
03
2019
accepted:
15
10
2019
entrez:
3
11
2019
pubmed:
5
11
2019
medline:
12
6
2020
Statut:
epublish
Résumé
Cannabis is commonly used for its medical properties. In particular, cannabis is purported to have beneficial effects on a wide range of neuropsychiatric conditions. Studies assessing mental health in cannabis dispensary users typically evaluate symptoms using self-report check lists, which provide limited information about symptom severity, and whether subjects meet criteria for a psychiatric diagnosis. There is, therefore, a need for studies which assess mental health in dispensary users with standardized and well validated scientific instruments, such as those used in clinical drug trials. One hundred medical cannabis users were recruited from a community dispensary. All subjects completed a structured clinical interview with the Mini-International Neuropsychiatric Interview (MINI). Subjects also completed the Perceived Stress Scale-10, PROMIS Fatigue Scale, PROMIS Sleep Disturbance Scale, Beck Depression Inventory, the Patient Health Questionnaire-15 and the Brief Pain Inventory. Details about cannabis use were also recorded. Lifetime prevalence of mental illness in this cohort was high, and a large proportion of subjects endorsed psychological symptoms. The proportion of subjects who met criteria for classification of a current psychiatric disorder was low for mood disorders, but high for anxiety disorders and substance abuse/dependence. Cannabis use differed between the main psychiatric conditions. The present results indicate that rates of mental illness may be high in medical cannabis dispensary users. Use of structured clinical assessments combined with standardized symptom severity questionnaires provide a feasible way to provide a more rigorous and detailed evaluation of conditions and symptoms in this population.
Sections du résumé
BACKGROUND
Cannabis is commonly used for its medical properties. In particular, cannabis is purported to have beneficial effects on a wide range of neuropsychiatric conditions. Studies assessing mental health in cannabis dispensary users typically evaluate symptoms using self-report check lists, which provide limited information about symptom severity, and whether subjects meet criteria for a psychiatric diagnosis. There is, therefore, a need for studies which assess mental health in dispensary users with standardized and well validated scientific instruments, such as those used in clinical drug trials.
METHODS
One hundred medical cannabis users were recruited from a community dispensary. All subjects completed a structured clinical interview with the Mini-International Neuropsychiatric Interview (MINI). Subjects also completed the Perceived Stress Scale-10, PROMIS Fatigue Scale, PROMIS Sleep Disturbance Scale, Beck Depression Inventory, the Patient Health Questionnaire-15 and the Brief Pain Inventory. Details about cannabis use were also recorded.
RESULTS
Lifetime prevalence of mental illness in this cohort was high, and a large proportion of subjects endorsed psychological symptoms. The proportion of subjects who met criteria for classification of a current psychiatric disorder was low for mood disorders, but high for anxiety disorders and substance abuse/dependence. Cannabis use differed between the main psychiatric conditions.
CONCLUSIONS
The present results indicate that rates of mental illness may be high in medical cannabis dispensary users. Use of structured clinical assessments combined with standardized symptom severity questionnaires provide a feasible way to provide a more rigorous and detailed evaluation of conditions and symptoms in this population.
Identifiants
pubmed: 31675939
doi: 10.1186/s12888-019-2324-z
pii: 10.1186/s12888-019-2324-z
pmc: PMC6825348
doi:
Substances chimiques
Medical Marijuana
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
335Références
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Schizophr Res. 2016 Oct;176(2-3):158-163
pubmed: 27499362
Pain. 2017 Jul;158(7):1373-1379
pubmed: 28328576
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Drug Alcohol Depend. 2017 Aug 1;177:1-13
pubmed: 28549263
J Psychoactive Drugs. 2015 Jan-Mar;47(1):18-23
pubmed: 25715068
J Nerv Ment Dis. 2013 Dec;201(12):1085-9
pubmed: 24284645
Cannabis Cannabinoid Res. 2016 Jun 01;1(1):131-138
pubmed: 28861489
J Psychoactive Drugs. 2016 Jan-Mar;48(1):50-5
pubmed: 26757234
Addict Behav. 1994 Jan-Feb;19(1):33-9
pubmed: 8197891
Addict Behav. 2017 Sep;72:14-20
pubmed: 28340421
BMC Res Notes. 2015 Sep 30;8:515
pubmed: 26423806
Ann Med. 2016;48(3):128-41
pubmed: 26912385
J Psychiatry Neurosci. 2015 Jul;40(4):219-21
pubmed: 26107348
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Psychopharmacology (Berl). 2019 Jun 22;:null
pubmed: 31230145
Ann Acad Med Singapore. 1994 Mar;23(2):129-38
pubmed: 8080219
Drug Alcohol Depend. 2018 May 1;186:10-15
pubmed: 29525698
PLoS One. 2016 Apr 05;11(4):e0152118
pubmed: 27046165
BMC Psychiatry. 2013 Mar 20;13:91
pubmed: 23514436
Hum Psychopharmacol. 2009 Oct;24(7):515-23
pubmed: 19693792
Psychiatry Res. 2016 Jun 30;240:336-342
pubmed: 27138828
Addict Behav. 2019 May;92:6-13
pubmed: 30553940
Neuropharmacology. 2017 Sep 15;124:89-104
pubmed: 28634109
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
J Clin Epidemiol. 2016 May;73:128-34
pubmed: 26939927
Cannabis Cannabinoid Res. 2016 Dec 01;1(1):244-251
pubmed: 28861496
Psychosom Med. 2002 Mar-Apr;64(2):258-66
pubmed: 11914441
CNS Drugs. 2010 Jul;24(7):595-609
pubmed: 20356315
J Affect Disord. 2019 Jan 1;242:165-171
pubmed: 30179790
Addict Behav. 2014 Oct;39(10):1537-42
pubmed: 24999989
Nord J Psychiatry. 2014 Aug;68(6):369-84
pubmed: 24228776
Am J Psychiatry. 2013 Dec;170(12):1413-22
pubmed: 23929175
Curr Neuropharmacol. 2017;15(6):800-814
pubmed: 27804883
CMAJ. 2015 Aug 11;187(11):E345-E346
pubmed: 26195580
Int Clin Psychopharmacol. 2014 May;29(3):125-37
pubmed: 24169026
J Pain Res. 2017 May 02;10:989-998
pubmed: 28496355
J Psychoactive Drugs. 2015 Nov-Dec;47(5):345-50
pubmed: 26595140
Psychol Med. 2014 Mar;44(4):797-810
pubmed: 23795762
Int J Health Policy Manag. 2016 May 25;5(8):453-456
pubmed: 27694657
Addiction. 2017 Dec;112(12):2206-2216
pubmed: 28696583
Psychopharmacology (Berl). 2017 May;234(9-10):1535-1547
pubmed: 28190084
Am J Psychiatry. 1985 Nov;142(11):1259-64
pubmed: 3904487
Addiction. 2015 Jun;110(6):904-19
pubmed: 25963869
Curr Pain Headache Rep. 2016 May;20(5):35
pubmed: 27068665
Clin J Pain. 2004 Sep-Oct;20(5):309-18
pubmed: 15322437
Eur J Clin Pharmacol. 2015 Apr;71(4):389-401
pubmed: 25627831
J Psychiatr Res. 2011 Aug;45(8):1027-35
pubmed: 21439576
Sleep. 2010 Jun;33(6):781-92
pubmed: 20550019
Int J Drug Policy. 2018 Sep;59:67-75
pubmed: 30029073
Addict Behav. 2015 Jan;40:91-5
pubmed: 25240105
J Stud Alcohol Drugs. 2016 May;77(3):515-20
pubmed: 27172585